CVS to Pay $315M to Settle Justice Department Case Over Opioid Prescriptions

Pharmacies CVS and its subsidiaries have reached a $315 million agreement to settle a Justice Department lawsuit alleging they unlawfully prescribed opioids, according to officials on Tuesday. The case, initiated in 2024, accused the healthcare company of dispensing excessive amounts of opioids to boost its profits while endangering public health and safety.

This settlement marks a significant step in the federal government's ongoing efforts to tackle the U.S. opioid crisis, as reported by Associate Attorney General Stanley Woodward.

CVS stated in a statement that its pharmacists were well-trained on the proper use of all medications and that the company implemented industry-leading programs to support them in making the best decisions for patients. The company strongly denied the lawsuit's claims, asserting that it disagreed with the allegations of wrongdoing. In 2024, CVS highlighted that pharmacists were pressured by vague, undefined, and constantly changing standards of practice when it came to filling opioid prescriptions.

The lawsuit, brought under President Joe Biden's administration, accused CVS of breaching the Controlled Substances Act by issuing illegitimate prescriptions for high-dose opioids, contributing to addiction and dependency. The Justice Department alleged that CVS filled a large volume of opioids based on prescriptions from known pill mills, providers who distribute drugs without a legitimate medical reason.

Poor staffing levels, along with performance metrics and incentive compensation policies, led pharmacists to hastily fill prescriptions without verifying their legitimacy, often billed to and reimbursed by Medicaid and other federal healthcare programs, according to the lawsuit.

As part of the settlement, CVS is required to establish additional safeguards to ensure prescriptions for opioids and other controlled substances are dispensed only when medically appropriate, stated Assistant Attorney General Brett Shumate, who oversees the Justice Department's Civil Division. Over the past decade, numerous drugmakers, wholesalers, pharmacies, and other entities have settled with U.S. governments in agreements totaling over $50 billion, primarily aimed at addressing the crisis that has been linked to more than 100,000 deaths annually in the U.S., though numbers have recently declined.

While most settlements have benefited state and local governments, the U.S. has also reached deals with major pharmacies like Walgreens and Walmart in recent years.